المؤلفون: Panos Papaspyridakos, Dieter Weingart, Konstantinos Vazouras, Nikos Mardas, Christiaan M. ten Bruggenkate, Eik Schiegnitz, Ralf Smeets, Mauricio G. Araújo, Stephen Barter, Hans-Peter Weber, Alberto Monje, Gary Finelle, Michael Payer, Nadine Brodala, Simon Storgård Jensen, Bo Chen, Hadi Gholami, Gustavo Avila-Ortiz, Johannes Kleinheinz, Jeffrey Ganeles, Stefan Fickl, Péter Windisch, Martina Stefanini, Vivianne Chappuis, Hideaki Katsuyama, Bilal Al-Nawas, André Barbisan de Souza, Ronald E. Jung, Asbjørn Jokstad, Christoph H. F. Hämmerle, Ricardo Faria Almeida, Chatchai Kunavisarut

المساهمون: Jung, Ronald E., Al-Nawas, Bilal, Araujo, Mauricio, Avila-Ortiz, Gustavo, Barter, Stephen, Brodala, Nadine, Chappuis, Vivianne, Chen, Bo, De Souza, Andre, Almeida, Ricardo Faria, Fickl, Stefan, Finelle, Gary, Ganeles, Jeffrey, Gholami, Hadi, Hammerle, Christoph, Jensen, Simon, Jokstad, Asbjørn, Katsuyama, Hideaki, Kleinheinz, Johanne, Kunavisarut, Chatchai, Mardas, Niko, Monje, Alberto, Papaspyridakos, Pano, Payer, Michael, Schiegnitz, Eik, Smeets, Ralf, Stefanini, Martina, ten Bruggenkate, Christiaan, Vazouras, Konstantino, Weber, Hans-Peter, Weingart, Dieter, Windisch, Péter, University of Zurich

المصدر: Jung, R E, Al-Nawas, B, Araujo, M, Avila-Ortiz, G, Barter, S, Brodala, N, Chappuis, V, Chen, B, De Souza, A, Almeida, R F, Fickl, S, Finelle, G, Ganeles, J, Gholami, H, Hammerle, C, Jensen, S, Jokstad, A, Katsuyama, H, Kleinheinz, J, Kunavisarut, C, Mardas, N, Monje, A, Papaspyridakos, P, Payer, M, Schiegnitz, E, Smeets, R, Stefanini, M, Ten Bruggenkate, C, Vazouras, K, Weber, H-P, Weingart, D & Windisch, P 2018, ' Group 1 ITI Consensus Report : The influence of implant length and design and medications on clinical and patient-reported outcomes ', Clinical Oral Implants Research, vol. 29, no. S16, pp. 69-77 . https://doi.org/10.1111/clr.13342
Jung, R E, Al-Nawas, B, Araujo, M, Avila-Ortiz, G, Barter, S, Brodala, N, Chappuis, V, Chen, B, de Souza, A, Almeida, R F, Fickl, S, Finelle, G, Ganeles, J, Gholami, H, Hammerle, C, Jensen, S, Jokstad, A, Katsuyama, H, Kleinheinz, J, Kunavisarut, C, Mardas, N, Monje, A, Papaspyridakos, P, Payer, M, Schiegnitz, E, Smeets, R, Stefanini, M, ten Bruggenkate, C, Vazouras, K, Weber, H-P, Weingart, D & Windisch, P T 2018, ' Group 1 ITI Consensus Report: The influence of implant length and design and medications on clinical and patient-reported outcomes ', Clinical Oral Implants Research, vol. 29, pp. 69-77 . https://doi.org/10.1111/clr.13342
Jung, Ronald E; Al-Nawas, Bilal; Araujo, Mauricio; Avila-Ortiz, Gustavo; Barter, Stephen; Brodala, Nadine; Chappuis, Vivianne; Chen, Bo; De Souza, Andre; Almeida, Ricardo Faria; Fickl, Stefan; Finelle, Gary; Ganeles, Jeffrey; Gholami, Hadi; Hammerle, Christoph; Jensen, Simon; Jokstad, Asbjørn; Katsuyama, Hideaki; Kleinheinz, Johannes; Kunavisarut, Chatchai; ... (2018). Group 1 ITI Consensus Report: The influence of implant length and design and medications on clinical and patient-reported outcomes. Clinical oral implants research, 29(S16), pp. 69-77. Wiley-Blackwell 10.1111/clr.13342 <http://dx.doi.org/10.1111/clr.13342>
Jung, R E, Al-Nawas, B, Araujo, M, Avila-Ortiz, G, Barter, S, Brodala, N, Chappuis, V, Chen, B, De Souza, A, Almeida, R F, Fickl, S, Finelle, G, Ganeles, J, Gholami, H, Hammerle, C, Jensen, S, Jokstad, A, Katsuyama, H, Kleinheinz, J, Kunavisarut, C, Mardas, N, Monje, A, Papaspyridakos, P, Payer, M, Schiegnitz, E, Smeets, R, Stefanini, M, ten Bruggenkate, C, Vazouras, K, Weber, H P, Weingart, D & Windisch, P 2018, ' Group 1 ITI Consensus Report : The influence of implant length and design and medications on clinical and patient-reported outcomes ', Clinical Oral Implants Research, vol. 29, no. S16, pp. 69-77 . https://doi.org/10.1111/clr.13342

مصطلحات موضوعية: medicine.medical_treatment, Osteoporosis, biological complications, Dentistry, Osteoporosis/complications, meta-analysi, law.invention, Proton Pump Inhibitors/adverse effects, 0302 clinical medicine, Randomized controlled trial, law, Radiography, Dental, Dental Restoration Failure, Dental implant, humans, 610 Medicine & health, clinical decision-making, dental implant, Diphosphonates, narrow diameter, 3504 Oral Surgery, Jaw, Edentulous, Partially, 05 social sciences, Dental Implantation, Endosseous, Implant failure, drug, small dental implant, VDP::Medisinske Fag: 700::Klinisk odontologiske fag: 830, failure, clinical decision‐making, Diphosphonates/adverse effects, Meta-analysis, randomized controlled trials, epidemiology, medication, Oral Surgery, Selective Serotonin Reuptake Inhibitors, Consensus, review, survival, 03 medical and health sciences, 10068 Clinic of Reconstructive Dentistry, SDG 3 - Good Health and Well-being, dental implants, 0502 economics and business, medicine, short dental implants, Humans, biological complication, Patient Reported Outcome Measures, human, Survival rate, small dental implants, Dental Implants, business.industry, Jaw, Edentulous, Partially/rehabilitation, short dental implant, Proton Pump Inhibitors, 030206 dentistry, medicine.disease, endosseous implant, Survival Analysis, VDP::Medical disciplines: 700::Clinical dentistry disciplines: 830, Dental Prosthesis Design, meta‐analysis, Relative risk, randomized controlled trial, 050211 marketing, Implant, Serotonin Uptake Inhibitors/adverse effects, business, osteotomy, Systematic Reviews as Topic

الوصف: The following article: Jung, R.E., Al-Nawas, B., Araujo, M., Avila-Ortiz, G., Barter, S., Brodala, N., ... Windisch, P. (2018). Group 1 ITI Consensus Report: The influence of implant length and design and medications on clinical and patient-reported outcomes. Clinical Oral Implants Research, 29(S16), 69-77, can be accessed at https://doi.org/10.1111/clr.13342. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. Objectives: The aim of Working Group 1 was to address the influence of different local (implant length, diameter, and design) and systemic (medications) factors on clinical, radiographic, and patient‐reported outcomes in implant dentistry. Focused questions on (a) short posterior dental implants (≤6 mm), (b) narrow diameter implants, (c) implant design (tapered compared to a non‐tapered implant design), and (d) medication‐related dental implant failures were addressed. Materials and methods: Four systematic reviews were prepared in advance of the Consensus Conference and were discussed among the participants of Group 1. Consensus statements, clinical recommendations, and recommendations for future research were based on structured group discussions until consensus was reached among the entire expert Group 1. The statements were then presented and accepted following further discussion and modifications as required by the plenary. Results: Short implants (≤6 mm) revealed a survival rate ranging from 86.7% to 100%, whereas standard implant survival rate ranged from 95% to 100% with a follow‐up from 1 to 5 years. Short implants demonstrated a higher variability and a higher Risk Ratio [RR: 1.24 (95% CI: 0.63, 2.44, p = 0.54)] for failure compared to standard implants. Narrow diameter implants (NDI) have been classified into three categories: Category 1: Implants with a diameter of Tapered versus non‐tapered implants demonstrated only insignificant differences regarding clinical, radiographic, and patient‐reported outcomes. The intake of certain selective serotonin reuptake inhibitors and proton pump inhibitors is associated with a statistically significant increased implant failure rate. The intake of bisphosphonates related to the treatment of osteoporosis was not associated with an increased implant failure rate. Conclusions: It is concluded that short implants (≤6 mm) are a valid option in situations of reduced bone height to avoid possible morbidity associated with augmentation procedures; however, they reveal a higher variability and lower predictability in survival rates. Narrow diameter implants with diameters of 2.5 mm and more demonstrated no difference in implant survival rates compared to standard diameter implants. In contrast, it is concluded that narrow diameter implants with diameters of less than 2.5 mm exhibited lower survival rates compared to standard diameter implants. It is further concluded that there are no differences between tapered versus non‐tapered dental implants. Certain medications such as selective serotonin reuptake inhibitors and proton pump inhibitors showed an association with a higher implant failure rate.

وصف الملف: ELETTRONICO; Jung_et_al-2018-Clinical_Oral_Implants_Research-2.pdf - application/pdf; application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c845b319a956a619be8b3b1e9def10f
http://hdl.handle.net/11585/673401

المؤلفون: Per Birger Johansen, Bjarne Nesgaard Andersen, Bo Abrahamsen

المصدر: Andersen, B N, Johansen, P B & Abrahamsen, B 2016, ' Proton pump inhibitors and osteoporosis ', Current Opinion in Rheumatology, vol. 28, no. 4, pp. 420-425 . https://doi.org/10.1097/BOR.0000000000000291

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Bone density, Proton, medicine.drug_class, proton pump inhibitor, Osteoporosis, Proton-pump inhibitor, 030209 endocrinology & metabolism, Drug Prescriptions, Proton Pump Inhibitors/adverse effects, 03 medical and health sciences, Osteoporotic Fractures/chemically induced, 0302 clinical medicine, Rheumatology, Bone Density, Risk Factors, Internal medicine, medicine, Humans, calcium, business.industry, Bone Density/drug effects, Proton Pump Inhibitors, fractures, medicine.disease, osteoporosis, Drug Prescriptions/standards, 030211 gastroenterology & hepatology, business, bone mineral density, Osteoporosis/chemically induced, Osteoporotic Fractures

الوصف: PURPOSE OF REVIEW: The purpose of the review is to provide an update on recent advances in the evidence based on proton pump inhibitors (PPI) as a possible cause of osteoporosis and osteoporotic fractures. This review focuses, in particular, on new studies published in the last 18 months and a discussion of these findings and how this has influenced our understanding of this association, the clinical impact and the underlying pathophysiology.RECENT FINDINGS: New studies have further strengthened existing evidence linking use of PPIs to osteoporosis. Short-term use does not appear to pose a lower risk than long-term use. There is a continued lack of conclusive studies identifying the pathogenesis. Direct effects on calcium absorption or on osteoblast or osteoclast action cannot at present plausibly explain the mechanism.SUMMARY: The use of PPIs is a risk factor for development of osteoporosis and osteoporotic fractures. However, as the direct pathogenesis remains unclear, specific points of intervention are lacking, other than being vigilant in regard to the indication for prescribing PPIs and to use the lowest effective dose where PPIs cannot be avoided.

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cc522575f92a088b07c91acb1efa05c
https://pubmed.ncbi.nlm.nih.gov/27224743